Hepatocellular Carcinoma by BCLC Stage, Liver Cancer, Lung Cancer, NSCLC Stage IIIB, NSCLC Stage IV
Conditions
Brief summary
This is a phase I clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce our patented product IKC (Immune Killer Cells). The IKC will then infused back into the patient to treat the cancer. Each patient will receive a total of six infusions.
Detailed description
This is a phase I clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce the patented product IKC (Immune Killer Cells). The IKC will then infused back into the patient to treat the cancer. Each patient will receive a total of six infusions. For each indication (cancer of the lung or liver) 10 patients are anticipated to be recruited, making a total of 20 subjects. All subjects will receive treatment as this is a single-arm study.
Interventions
BIOLOGICALImmune Killer Cells (IKC)
Sponsors
Ivy Life Sciences, Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. subjects had voluntarily given written informed consent 2. subjects had CT scan on lung or liver tumors within the past 4 weeks of the screening visit 3. subjects who were histologically or pathologically confirmed with locally advanced or metastatic lung cancer or HCC 4. subjects who did not have valid therapy, ever failed with other therapy, or refused or were not appropriate for other therapies for lung cancer or HCC 5. subjects' ECOG performance status ≤ 2 6. subjects with life expectancy ≥ 3 months
Exclusion criteria
1. subjects with medical history of gout 2. subjects who had participated other clinical trials within 4 weeks before the screening visit 3. subjects with positive result of HIV or HTLV test within 4 weeks before the screening visit 4. subjects with clinically significant diseases other than cancer 5. subjects with myocardial infraction, stroke, or congestive heart failure within 3 months before the screening visit 6. female subjects who were pregnant or lactating or women of child-bearing potential but unable to take adequate contraception 7. subjects with history of alcohol, drug or other substance abuse 8. subjects with disease of bacteremia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events [Safety] | 5 months | Adverse Events (AE) and Serious Adverse Events (SAE) will be recorded and evaluated for their relationship to the treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response Evaluation Criteria in Solid Tumors (RECIST) | 4 months | Record net changes of tumor sizes |
| Quality of Life (QOL) | 5 months | The assessment will be performed using The World Heath Organization Quality of Life Questionnaire (WHOQOL) This questionnaire produces a quality of life profile. It is possible to derive four domain scores. The four domain scores denote an individual's perception of quality of life in each particular domain (1. Physical health 2. Psychological 3. Social relationships 4. Environmental) Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life). The mean score of items within each domain is used to calculate the domain score (min: 0 max: 100) Domain scores are then calculated (divide domain score by 4) to produce a final QOL Score (i.e. higher scores denote higher quality of life min: 0 max:100). |
Outcome results
None listed